Roche (ROG) Given a CHF 325 Price Target at Goldman Sachs Group
Roche (VTX:ROG) received a CHF 325 price objective from equities research analysts at Goldman Sachs Group in a report released on Tuesday. The firm currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s price objective suggests a potential upside of 46.00% from the company’s current price.
Several other brokerages have also recently commented on ROG. Jefferies Group set a CHF 300 target price on shares of Roche and gave the stock a “buy” rating in a report on Friday, January 5th. UBS Group set a CHF 260 target price on shares of Roche and gave the stock a “neutral” rating in a report on Monday, January 8th. JPMorgan Chase & Co. set a CHF 300 target price on shares of Roche and gave the stock a “buy” rating in a report on Thursday, January 4th. Sanford C. Bernstein set a CHF 262 price target on shares of Roche and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, Morgan Stanley set a CHF 260 price target on shares of Roche and gave the stock a “neutral” rating in a research report on Friday, December 1st. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of CHF 257.20.
Roche (VTX ROG) opened at CHF 222.60 on Tuesday. Roche has a fifty-two week low of CHF 214.30 and a fifty-two week high of CHF 273. The company has a market cap of $192,200.00 and a P/E ratio of 22.17.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.